:strip_icc()/s04.video.glbimg.com/x720/8965027.jpg)
[ad_1]
The main input for the production of vaccine from the company Astrazeneca, produced in Brazil in association with University of Oxford and Oswaldo Cruz Foundation (Fioruz), is manufactured in China.
The information was published by columnist Mônica Bergamo, from the Folha de S. Paulo newspaper.
According to her, 15 million doses of the active pharmaceutical ingredient (API) will come from China to Brazil in December, to manufacture the first doses of the vaccine developed by Oxford at the Bio-Manguinhos Institute, linked to Fiocruz.
The information was confirmed by the infectious diseases specialist and researcher at Fiocruz, Júlio Croda, during an interview with GloboNews.
“It has a Chinese component like any product, right? The masks we use, the respirators that were imported, most of the medical products today are from China. So it is normal for most vaccines to have some Chinese component. . We cannot be xenophobic to discriminate a product based on its origin. We have to evaluate the studies and Anvisa really evaluates these results regardless of the origin of the country and identifies if they are results that prove that safety is the effectiveness of the vaccine “.
IFA is the active ingredient in the vaccine, the concentrated vaccine. The Oxford drug is in phase three, with testing on volunteers.
Astrazeneca has already received almost R $ 2 billion in investments from the federal government.
Production of vaccines developed in collaboration with the University of Oxford – Photo: Rede Globo
The Coronavac vaccine, produced by the pharmaceutical company Sinovac, is in the same phase as the immunizer produced by Astrazeneca.
Butantan will produce vaccines at the national level, with imported supplies from China, with the prior approval of the National Health Surveillance Agency (Anvisa).
This week, Health Minister Eduardo Pazuello even announced the intention and purchase of Coronavac, but then-President Jair Bolsonaro said he would not buy the vaccine from China and ordered the cancellation of the agreement.
“I had already canceled it, the president is me, I do not renounce my authority. Even because I would be buying a vaccine that does not interest anyone, except us. I do not know if there is a huge price in all this.” pay for this vaccine in China. ”
On Thursday (22), the director of the Butantan Institute, Dimas Covas, told the Folha de S. Paulo newspaper on the Internet that Anvisa is taking too long to authorize the importation of raw material from the pharmaceutical company Sinovac to produce the Coronavac vaccine in Brazil. .
In an interview with TV Globo, Dimas Covas said that he hopes the agency will expedite the authorization.
